James is a Technical Advisor with more than a decade of life sciences research experience who assists clients with patent drafting and prosecution and strategic patent portfolio management. He has a broad range of capabilities spanning the areas of antibody-based therapies, cancer biology, immunology, nanoparticles, CRISPR-gene editing, personalized medicine, mass spectrometry instrumentation and data analysis, miRNAs, drug screening platform development, molecular diagnostics, 3D organoid culture systems, immunotoxins, protein structure-function analysis, extracellular vesicles, mouse models of disease, and cellular therapies.
Prior to joining Mintz, James was a postdoctoral fellow at the Johns Hopkins University School of Medicine and a fellow in the school’s patent law training program. In his patent fellowship, he prepared patentability assessments for life sciences patents, drafted freedom to operate analyses, and performed IP due diligence and patent landscape analysis to assist in the strategic planning of portfolios. His research work included identifying a novel role for cell adhesion to regulate cell metabolism and mitochondrial function in metastatic breast cancer. He also developed an in vitro co-culture system to screen novel compounds to inhibit brain metastasis and performed pre-clinical drug screens on primary breast cancer organoids to identify potential drug treatment compounds. Earlier, as a research associate at a clinical-stage biopharmaceutical company, he developed a phage display screening platform and engineered next-generation immunotoxins to identify novel cancer therapeutics, performed pre-clinical evaluation of immunotoxins, and helped draft US and international patent applications related to this research.
While earning his PhD, James identified a TGFβ-regulated miRNA linked to endothelial cell function during tumor angiogenesis and tumor growth and made presentations about the findings at three international conferences. He also designed in vivo nanoparticle studies to test novel cancer therapies through the delivery of miRNA, molecular therapeutics, or both to specific cell types and created mouse models to audit extracellular vesicles and endothelial cells in healthy and diseased tissues. He also received a postdoctoral fellowship grant from the National Cancer Institute to focus on training for fundamental cancer research.
- Co-author, Reporter mice for isolating and auditing cell type specific extracellular vesicles in vivo, Genesis (June 2020)
- Co-author, A miRNA signature in endothelial cell-derived extracellular vesicles in tumor bearing mice, Scientific Reports (November 2019)
- Co-author, Quaking orchestrates a post-transcriptional regulatory network of endothelial cell cycle progression critical to angiogenesis and metastasis, Oncogene (June 2019)
- Co-author, Endothelial miR-30c suppresses tumor growth via inhibition of TGFβ-induced Serpine1, Journal of Clinical Investigation (March 2019)
Recognition & Awards
Gordon Research Conference: Endothelial Cell Phenotypes in Health and Disease: Graduate Student Travel Award (2016)
North American Vascular Biology Organization Annual Meeting: Graduate Student Travel Award (2015)